Jazz Pharmaceuticals (JAZZ) investor relations material

Commercial performance and financial outlook

• Achieved record revenue in 2025 with 5% growth, led by Xywav (12%), Epidiolex (9%), and strong Modeyso uptake.

• Secured 21st consecutive year of growth and targeting a 22nd with 2026 revenue guidance of $4.25–$4.5 billion, representing 2.5% growth at midpoint.

• Acquisition of Chimerix and Modeyso approval provided significant financial benefits, including $200 million in deferred tax assets and a $200 million priority review voucher sale.

• Over half of 2025 revenue came from non-sleep products, expected to grow double digits in 2026.

• Maintains strong financial resources with $2.5 billion in cash and investments, supporting future corporate development.

Pipeline and R&D progress

• Practice-changing data in first-line maintenance small cell lung cancer with Zepzelca plus atezolizumab.

• Zanidatamab showed unprecedented overall survival in first-line GEA; FDA submission completed, included in RTOR, and granted Breakthrough Therapy designation.

• Anticipates zanidatamab approval and launch later in 2026, with ongoing expansion into breast and other cancers.

• Early-stage assets in KRAS, NRAS, and conditionally activated interferon alpha advancing through phase I.

• First internally generated asset entered the clinic in epilepsy, with more expected from in-house research.

Strategic investments and corporate development

• Focused on investing in marketed products and pipeline, especially in epilepsy and oncology.

• Seeks to expand into new rare disease areas, with initial investments likely post proof-of-concept.

• Recent deals, such as the Saniona licensing in epilepsy, illustrate willingness to invest across development stages.

• Additional management focus on corporate development with new Chief Business Officer.

• Expects to pursue more acquisitions similar to Chimerix and expand rare disease presence in coming years.